Author: Mokhtar

  • Save Our Bones Bulletin: Skeletal Stem Cells Control the Effects of Aging;  Pain management therapy offers an alternative to painkillers;  New dangers of aspartame discovered

    Save Our Bones Bulletin: Skeletal Stem Cells Control the Effects of Aging; Pain management therapy offers an alternative to painkillers; New dangers of aspartame discovered

    This month’s Save Our Bones Bulletin brings you the latest in stem cell research, mental approaches to physical pain and a shocking revelation about a commonly used sweetener.

    First, we’ll delve into a study conducted on mice that uncovered a pathway that regulates bone loss. The researchers believe this discovery may also revitalize bone regeneration in humans.

    Next, you’ll discover a therapeutic approach that uses brain education to reduce or eliminate back pain.

    Finally, we will discuss new disturbing findings about the artificial sweetener aspartame.

    Study in mice reveals pathway that regulates age-related bone loss

    Researchers from the NYU Grossman School of Medicine discovered that they could increase bone mass in mice by blocking the signaling pathway of skeletal stem cells.

    The signaling pathway being investigated is called Notch. This series of signals involves multiple compounds that interact in a specific order to determine the final shape that skeletal stem cells will take.

    The researchers studied RNA sequencing in young and old mouse bones to observe the relationship between activity in the Notch signaling pathway, aging and bone formation.

    Relevant excerpt

    “The researchers found that the Notch pathway becomes abnormally active, causing the cells to shift toward a fate that increases fatty degeneration of the bone marrow. When they genetically engineered mice to lack Nicastrin, a core part of the Notch signaling chain reaction, the stem cells were returned to the bone-making cell pathway, increasing bone formation “even beyond what is seen in young mice.”1

    This discovery sheds light on the ways in which stem cell signaling changes with age and can negatively impact bone health. Hopefully, with further research, we can learn how to naturally support this system to increase bone production.

    However, it is likely that the Notch pathway will be targeted by new anti-osteoporosis drugs.

    Short content

    Researchers found that blocking a connection in the skeletal stem cell signaling pathway could increase bone formation in mice. This change reversed the age-related decline in bone mass. It may become the target of new drug development.

    Back pain is not on your mind, but relief can be

    In a study on the impact of pain perception, two-thirds of participants reduced or eliminated their back pain after learning to interpret pain signals as less harmful.

    The study participants underwent pain coping therapy, which taught them to reinterpret pain signals to the brain. By understanding their brain’s role in creating the pain experience, they were able to reduce or end the pain they were experiencing.

    Relevant excerpt

    “This study is critical because patients’ pain attributions are often inaccurate. We found that very few people believed that their brains had anything to do with their pain,” says [lead study author] Dr. [Yoni] Ashar. “These results show that changing perspectives on the role of the brain in chronic pain can allow patients to experience better outcomes and outcomes.”

    The team hopes that these findings will encourage medical professionals to discuss possible non-biomedical causes of pain with their patients.”2

    This study is an excellent example of how research can help identify non-pharmaceutical interventions for common conditions.

    Chronic pain is a serious and widespread problem. New approaches to treating it, without resorting to harmful and potentially addictive painkillers, could pave the way for healthier relief options.

    Short content

    Research into pain management therapy has shown that participants can alleviate or completely eliminate their back pain by learning to reinterpret pain signals. These findings validate the effectiveness of a non-pharmaceutical approach to pain relief.

    Artificial sweetener aspartame linked to hereditary problems

    Researchers from the Florida State University College of Medicine linked the artificial sweetener aspartame to learning and memory problems in mice.

    In the study, the male mice were given aspartame in amounts considered safe by the FDA. However, not only did they show cognitive problems, but their offspring also showed problems with spatial learning and memory.

    Relevant excerpt

    ”The mice in the study were divided into three groups for 16 weeks. One group drank only water, the second group drank water with aspartame, equivalent to two diet soft drinks per day, and the third group drank water with aspartame, equivalent to four diet soft drinks per day.

    The mice’s learning ability was tested at different intervals using a Y-maze and a Barnes maze, where the mice had to find a ‘safe’ box among 40 options. Mice that were not given aspartame found the box quickly, while those that consumed the sweetener took significantly longer.”3

    This study should give diet soda drinkers pause. Clearly, the effects of artificial sweeteners are still emerging – and they are not positive.

    Instead of aspartame, opt for a natural sweetener such as stevia leaf or monk fruit extract as a sugar substitute.

    Although this substitution is simple, it is impossible to avoid every potentially toxic substance. In today’s world we are surrounded by chemicals and artificial compounds.

    You can give your body a break with the Osteoporosis Fresh Start Cleanse. It is a 7-day rejuvenating program designed to boost your body’s ability to maintain bone health.

    Short content

    A study on mice found that consuming aspartame reduced the mice’s learning ability. Furthermore, the effects were inherited by the mice’s offspring. This shows that aspartame, often used to sweeten diet soft drinks, can have a negative impact on the brain.

    What this means for you

    New research will likely result in another barrage of dangerous drugs, but other discoveries could help us learn healthy habits. Talk to your doctor about non-pharmaceutical pain management programs, and the next time you want something sweet, skip the aspartame.

    These helpful diversions may be small, but they add up to a huge difference in your well-being.

    The Osteoporosis Reversal Program uses a similar strategy. It’s not a one-time quick fix or a magic trick. The ORP is a collection of tools and strategies that include nutrition, physical activity, and daily habits. This holistic approach is the foundation of the ORP’s continued success.

    You don’t have to change everything in one day. But every day you can change something. Over time, you will find yourself turning into the healthy, vibrant, independent person you have always wanted to be.

    References

    1 https://www.geengnews.com/topics/translational-medicine/bone-loss-lessened-by-blocking-abnormal-stem-cell-signal/

    2 https://studyfinds.org/chronic-backpain-brain/

    3 https://studyfinds.org/aspartame-learning-memory/



    Source link

  • Meucci RD, Fassa AG, Faria NM. Prevalence of chronic low back pain: systematic review. Rev. Saude Publica. 2015;49:1. https://doi.org/10.1590/S0034-8910.2015049005874.

    Article PubMed PubMed Central Google Scholar

  • Ay S, Evcik D. Depression and quality of life in patients with chronic low back pain. Department of Physical Medicine and Rehabilitation. Ankara New Medical Journal. 2008; 25:228–31.

    Google Scholar

  • Bogduk N. On the definitions and physiology of back pain, referred pain and radicular pain. Pain. 2009;147(1–3):17–9. https://doi.org/10.1016/j.pain.2009.08.020.

    Article PubMed Google Scholar

  • van Tulder M, Becker A, Bekkering T, Breen A, del Real MTG, Hutchinson A, Bart Koes B, Laerum E, Malmivaara A. Chapter 3 European guidelines for the treatment of acute non-specific low back pain in primary care. Eur Spine J. 2006; 15:169–91. https://doi.org/10.1007/s00586-006-1071-2.

    Article Google Scholar

  • Hayden JA, Ellis J, Ogilvie R, Malmivaara A, van Tulder MW. Exercise therapy for chronic low back pain. Cochrane Database System Rev. 2021;28(9):CD009790. https://doi.org/10.1002/14651858.CD009790.pub2.

    Article Google Scholar

  • Allen RJ. Physical agents used by physiotherapists in the treatment of chronic pain. Phys Med Rehabil Clin N Am. 2006; 17:315–45. https://doi.org/10.1016/j.pmr.2005.12.007.

    Article PubMed Google Scholar

  • Qaseem A, Wilt TJ, McLean RM, Forciea MA, Clinical Guidelines Committee of the American College of Physicians, Denberg TD, Barry MJ, Boyd C, Chow RD, Fitterman N, Harris RP, Humphrey LL, Vijan S. Noninvasive treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline from the American College of Physicians. Ann Intern Med. 2017;166(7):514–30. https://doi.org/10.7326/M16-2367.

    Article PubMed Google Scholar

  • KramerJF. Ultrasound: evaluation of its mechanical and thermal effects. Arch Phys Med Rehabilitation. 1984; 65:223–7.

    CAS PubMed Google Scholar

  • Maxwell L. Therapeutic ultrasound: its effects on the cellular and molecular mechanisms of inflammation and repair. Physiotherapy. 1992; 78:421–6. https://doi.org/10.1016/S0031-9406(10)61528-3.

    Article Google Scholar

  • Kitchen S, Partridge C. Review of continuous and pulsed shortwave diathermy patterns. Physiotherapy. 1992; 78:243–52. https://doi.org/10.1016/S0031-9406(10)61434-4.

    Article Google Scholar

  • Unlu Z, Tasci S, Tarhan S, Pabuscu Y, Islak S. Comparison of 3 physiotherapy modalities for acute pain in lumbar disc herniation measured by clinical evaluation and magnetic resonance imaging. J Manipulative physiotherapy. 2008;31(3):191–8. https://doi.org/10.1016/j.jmpt.2008.02.001.

    Article Google Scholar

  • Ebadi S, Henschke N, Forogh B, Nakhostin Ansari N, van Tulder MW, Babaei-Ghazani A, Fallah E. Therapeutic ultrasound for chronic low back pain. Cochrane Database System Rev. 2020;7(7):CD009169. https://doi.org/10.1002/14651858.CD009169.pub3.

    Article PubMed Google Scholar

  • Seco J, Kovacs FM, Urrutia G. The efficacy, safety, effectiveness and cost-effectiveness of ultrasound and shock wave therapies for low back pain: a systematic review. Rug J 2011;11:966–77. https://doi.org/10.1016/j.spinee.2011.02.002.

    Article PubMed Google Scholar

  • Kreiner DS, Hwang SW, Easa JE, Resnick DK, Baisden JL, Bess S, Cho CH, DePalma MJ, Dougherty P 2nd, Fernand R, et al. North American Spine Society. An evidence-based clinical guideline for the diagnosis and treatment of lumbar disc herniation with radiculopathy. Rug J 2014;14(1):180–91. https://doi.org/10.1016/j.jmpt.2008.02.001.

    Article PubMed Google Scholar

  • Chapman JR, Norvell DC, Hermsmeyer JT, Bransford RJ, DeVine J, McGirt MJ, Lee MJ. Evaluation of common outcomes for measuring treatment success for chronic low back pain. Spine. 2011;36:S54–68. https://doi.org/10.1097/BRS.0b013e31822ef74d.

    Article PubMed Google Scholar

  • Chiarotto A, Maxwell LJ, Terwee CB, Wells GA, Tugwell P, Ostelo RW. Roland-Morris Disability Questionnaire and Oswestry Disability Index: which has better measurement properties for measuring physical functioning in non-specific low back pain? Systematic review and meta-analysis. Phys Ther. 2016;96(10):1620–37. https://doi.org/10.2522/ptj.20150420.

    Article PubMed Google Scholar

  • Yakut E, Düger T, Oksüz C, Yörükan S, Ureten K, Turan D, Frat T, Kiraz S, Krd N, Kayhan H, Yakut Y, Güler C. Validation of the Turkish version of the Oswestry Disability Index for patients with low backache. Spine. 2004;29(5):581–5.

    Article PubMed Google Scholar

  • True JEJ, Sherbourne CD. The MOS 36-item short health survey (SF-36). I. Conceptual framework and item selection. Medical care. 1992;30:473–83.

    Article PubMed Google Scholar

  • Demiral Y, Ergor G, Unal B, Semin S, Akvardar Y, Kivircik B, Alptekin K. Normative data and distinctive properties of short form 36 (SF-36) in Turkish urban population. BMC Public Health. 2006;6:247.

    Article PubMed PubMed Central Google Scholar

  • Ansari NN, Ebadi S, Talebian S, Naghdi S, Mazaheri H, Olyaei G, Jalaie S. A randomized, single-blind, placebo-controlled clinical trial of the effect of continuous ultrasound on low back pain. Electromyogr Clin Neurophysiol. 2006;46(6):329–36.

    CAS PubMed Google Scholar

  • Saghaei M. Random assignment software for parallel-group randomized trials. BMC Med Res Method. 2004;4:26. https://doi.org/10.1186/1471-2288-4-26.

    Article PubMed PubMed Central Google Scholar

  • Schulz KF, Altman DG, Moher D, CONSORT group. CONSORT 2010 Statement: Updated Guidelines for Reporting Randomized Parallel Group Trials. BMJ. 2010;2010(340):332. https://doi.org/10.1136/bmj.c332.

    Article Google Scholar

  • Robertson VJ, Baker KG. A review of therapeutic ultrasound: effectiveness studies. Phys Ther. 2001;81(7):1339–50.

    Article CAS PubMed Google Scholar

  • Miller DL, Smith NB, Bailey MR, Czarnota GJ, Hynynen K, Makin IR. Bioeffects Committee of the American Institute of Ultrasound in Medicine. Overview of therapeutic ultrasound applications and safety considerations. J Echo Med. 2012;31(4):623–34. https://doi.org/10.7863/jum.2012.31.4.623.

    Article PubMed PubMed Central Google Scholar

  • Noori SA, Rasheed A, Aiyer R, Jung B, Bansal N, Chang KV, Ottestad E, Gulati A. Therapeutic ultrasound for pain management in chronic low back pain and chronic neck pain: a systematic review. Pain Med. 2020;7(21):1482–93. https://doi.org/10.1093/pm/pny287.

    Article Google Scholar

  • Haile G, Hailemariam TT, Haile TG. Effectiveness of ultrasound therapy in the treatment of chronic nonspecific low back pain: a systematic review. J Pain Res. 2021;14:1251–7. https://doi.org/10.2147/JPR.S277574.

    Article PubMed PubMed Central Google Scholar

  • Goats GC. Continuous shortwave diathermy (radio frequency). Br J Sports Med. 1989;23(2):123–7. https://doi.org/10.1136/bjsm.23.2.123.

    Article CAS PubMed PubMed Central Google Scholar

  • Benincá IL, de Estéfani D, Pereira de Souza S, Weisshahn NK, Haupenthal A. Tissue heating in different shortwave diathermy methods: a systematic review and narrative synthesis. J Bodyw Mov Ther. 2021;28:298–310. https://doi.org/10.1016/j.jbmt.2021.07.031.

    Article PubMed Google Scholar

  • Dos Reis do Nascimento DM, Raab FGC, Silva GLH, de Andrade AM, Ferreira PML, Silveira GAR, Brandt de Macedo AC. Immediate analgesic effect of two forms of short-wave diathermy in chronic low back pain: study protocol for a randomized controlled trial. Pain management. 2022;12(2):131–9. https://doi.org/10.2217/pmt-2021-0026.

    Article CAS PubMed Google Scholar

  • Abdulla FA, Alsaadi S, Sadat-Ali M, Alkhamis F, Alkawaja H, Lo S. Effects of pulsed low-frequency magnetic field therapy on pain intensity in patients with chronic low back musculoskeletal pain: study protocol for a randomized double-blind placebo-controlled trial. BMJ opened. 2019;9(6):e024650. https://doi.org/10.1136/bmjopen-2018-024650.

    Article PubMed PubMed Central Google Scholar

  • Shields N, Gormley J, O’Hare N. Shortwave diathermy: a review of existing clinical trials. Phys Ther Rev. 2001;6(2):101–18. https://doi.org/10.1002/pri.259.

    Article Google Scholar

  • Paladini LH, Almeida N, Korelo RIG, Michel de Macedo R, Guarita-Souza LC, Zotz TGG, Brandt de Macedo AC. Shortwave therapy in patients with chronic low back pain: a systematic review. Column/Column. 2020;19(3):218–22. https://doi.org/10.1590/S1808-185120201903219301.

    Article Google Scholar

  • Karasel S, Oncel S, Sonmez I. The effect of shortwave diathermy and exercise on depressive feelings in patients with chronic low back pain. Med Arch. 2021;75(3):216–20. https://doi.org/10.5455/medarh.2021.75.216-220.

    Article PubMed PubMed Central Google Scholar

  • Shakoor MA, Rahman MS, Moyeenuzzaman M. Effects of deep heat therapy on patients with chronic low back pain. Mymensingh Med J. 2008;17(2):32–8.

    Google Scholar

Source link

  • Catalyst OrthoScience announces Amy Ables, Ph.D.  as Chief Strategy Officer

    Catalyst OrthoScience announces Amy Ables, Ph.D. as Chief Strategy Officer

    Amy Ables Headshot2

    NAPLES, FL, November 20, 2023–(BUSINESS WIRE)–Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has appointed Amy Ables, Ph.D. as the organization’s Chief Strategy Officer, effective immediately.

    “The board and I are pleased that an executive with the experience and leadership of Dr. Ables is joining our team at Catalyst OrthoScience,” said Carl O’Connell, CEO and president of Catalyst. “We are committed to building a world-class organization focused on the success of our customers and our impact in the marketplace. The leadership of Dr. Ables will help make that vision a reality and guide us as we build greater capabilities and organizational competence to accelerate growth and scale our operations.”

    “I am grateful and excited to embrace this opportunity with the Catalyst team and return to my professional roots in shoulder orthopedics,” said Ables. “I look forward to contributing with strength and vision and driving our efforts toward growth and excellence with strategies that are both responsive to the present and aligned with the necessary investments for our future success.”

    Ables brings nearly 20 years of medical device experience to Catalyst, including more than a decade in upper extremity orthopedics. She held leadership positions in sales, marketing, medical education and sales training at Tornier and Wright Medical before joining ATEC Spine.

    Most recently, Ables served as Vice President of Customer Engagement and Sales Excellence at Cutera, a medical aesthetics organization. Before Cutera and during the peak of the COVID-19 pandemic, Ables served as Chief Learning Officer at Vyaire Medical, a global organization focused on respiratory care.

    Throughout her career, Ables has built a reputation as a strong customer-focused leader with an incomparable energy for continuous learning, strategy development and execution. Ables is a highly skilled, relatable leader who is driven to deliver results through team performance. She is a culture bearer who believes credibility is key and always leads by example.

    Ables earned a Bachelor of Science in Sports Medicine from the University of Charleston, a Masters in Biomechanics and a Ph.D. in human performance from Texas Woman’s University in 2003.

    About Catalyst OrthoScience Inc.

    Naples, Florida-based Catalyst OrthoScience was founded in 2014 by orthopedic surgeon Steven Goldberg, MD, who saw the need to make shoulder replacements less invasive, with fewer complications and a more natural-feeling shoulder after surgery. Catalyst disrupts the traditional approach to shoulder replacement surgery. Our total shoulder systems provide precision and accuracy in shoulder restoration, while preserving the patient’s bone and soft tissue. Catalyst has a growing portfolio of patents and patents pending on its distinctive offerings, which are available in the US. For more information, visit www.catalysstortho.com.

    Contacts

    Nancy McCarroll, CAO
    570.335.7417
    nmccarroll@catalystortho.com

    Source link

  • Bone Biologics Announces Closing of Registered Direct Offering at Market Prices Under Nasdaq Rules

    Bone Biologics Announces Closing of Registered Direct Offering at Market Prices Under Nasdaq Rules

    Bone Biologics 79

    BURLINGTON, Mass., November 20, 2023–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiology products for the spine fusion markets, today announced the closing of its previously announced registered direct offering at market-based prices under Nasdaq rules of an aggregate of 1,139,063 shares of its common stock at a purchase price of $0.64 per share. In a concurrent private placement, the Company also issued and sold unregistered warrants to purchase an aggregate of 1,139,063 shares of common stock. The unregistered warrants have an exercise price of $0.52 per share and are exercisable upon issuance and have a term of five and a half years from the date of issuance.

    HC Wainwright & Co. acted as exclusive placement agent for the offering.

    The gross proceeds to Bone Biologics from the offering were approximately $729,000, before deducting placement agent fees and other offering expenses payable by the Company. Bone Biologics currently intends to use the net proceeds from the offering to fund clinical trials, maintain and expand its patent portfolio and for working capital and other general corporate purposes.

    The shares of common stock offered in the registered direct offering (but excluding the unregistered warrants offered in the concurrent private placement and the shares of common stock underlying such unregistered warrants) were offered and sold by the Company pursuant to a shelf registration statement on Form S-3 (Registration No. 333-265872), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on June 28, 2022 and declared effective by the SEC on 11 July 2022. The offering of the common shares issued in connection with the registered direct offering was made only by means of a prospectus supplement forming part of the registration statement. A final prospectus supplement and accompanying base prospectus relating to the registered direct offering have been filed with the SEC and are available on the SEC’s website at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying base prospectus may also be obtained by contacting HC Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (212) 856-5711 or email to placements@hcwco.com.

    The offer and sale of the unregistered warrants in the private placement were made in a transaction not involving a public offering and have not been registered under Section 4(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act “) and/or Rule 506(b) of Regulation D promulgated thereunder and, together with the shares of common stock underlying such unregistered warrants, have not been registered under the Securities Act or the applicable state securities laws. Accordingly, the unregistered warrants offered in the private placement and the underlying common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable government bonds. securities laws.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration. or qualification under the securities laws of any such state or jurisdiction.

    About bone biology

    Bone Biologics was founded to pursue regenerative medicine for bones. The company is working with select strategic partners that will build on the preclinical research on the Nell-1 protein. Bone Biologics is currently focusing its development efforts for its bone graft replacement product on bone regeneration in spinal fusion procedures, while also having rights to applications in trauma and osteoporosis. For more information, please visit www.bonebiologics.com.

    Forward-Looking Statements

    Certain statements in this press release, including but not limited to the expected use of proceeds from the offering, as well as statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements.” statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in the forward-looking statements as a result of a number of factors, including, but not limited to, market and other conditions and factors including the Company’s ability to deliver our flagship product to develop NELL-1. and other proposed products, its ability to obtain patent protection for its technology, its ability to obtain necessary financing to develop products and conduct necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval for commercialize any product it may develop in the United States and to obtain any other regulatory approval necessary to market a product in other countries, its ability to commercialize any product it may develop market, its ability to create, sustain, manage or predict its growth; the ability to attract and retain key personnel; changes in the company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized development company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the The Company’s Form S-1, Form 10-K for the year ended December 31, 2022, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

    Contacts

    LHA Investor Relations
    Kim Sutton Golodetz
    212-838-3777
    kgolodetz@lhai.com

    Source link

  • Ginger Collagen Latte |  GF, DF |  BoneCoach™ Recipes – BoneCoach™

    Ginger Collagen Latte | GF, DF | BoneCoach™ Recipes – BoneCoach™

    Craving a comforting drink that’s perfect for any season?

    Try this!

    Our Ginger Collagen Latte recipe is a soothing drink that combines the warmth of a traditional ginger latte with the added benefits of collagen.

    Ginger may be beneficial for digestion, while collagen promotes skin elasticity and joint and bone health.

    Treat yourself to a cup of our Ginger Collagen Latte recipe today!

    Bone Coach Recipes |  Ginger Collagen Latte |  Bone loss Bone Healthy diet Nutrients Osteoporosis

    SERVES: 1

    TOTAL TIME: 5 minutes

    Ingredients

    1 1/2-inch piece fresh ginger, peeled and broken

    1 cup (250 ml) water

    1 scoop (26 g) collagen peptides

    1/4 teaspoon (1 ml) ground Ceylon cinnamon

    1-2 drops monk fruit sweetener

    1/2 cup (250 ml) non-dairy milk of your choice

    Directions

    1) Mix the ginger and water in a small pot. Bring to the boil and let it simmer for another 10 minutes. Remove the ginger root and whisk in the collagen, cinnamon and monk fruit.

    2) Froth the milk and pour the ginger tea over it. Sprinkle with extra Ceylon cinnamon and enjoy!

    Recipe created by BoneCoach™ Team Dietitian Amanda Natividad-Li, RD & Chef.

    Medical disclaimer

    The information shared above is for informational purposes only and is not intended as medical or nutritional therapy advice; it does not diagnose, treat or cure any disease or condition; it should not be used as a substitute or substitute for medical advice from physicians and trained medical professionals. If you are under the care of a healthcare professional or are currently taking prescription medications, you should discuss any changes in your diet and lifestyle or possible use of nutritional supplements with your doctor. You should not stop prescribed medications without first consulting your doctor.

    Source link

  • Exactech AI platform surpasses 100,000 joint replacement surgeries worldwide

    Exactech AI platform surpasses 100,000 joint replacement surgeries worldwide

    GAINESVILLE, Fla., Nov. 20, 2023–(BUSINESS WIRE)–Exactech, a developer and manufacturer of innovative implants, instrumentation and smart technologies for joint replacement surgery, today announced that its Active Intelligence® (AI) platform has a total of more than 100,000 exceeded joint replacement surgeries around the world.

    “We are proud to reach this incredible milestone of more than 100,000 patients with the support of our surgeon partners worldwide,” said Darin Johnson, CEO of Exactech. “As a leader in orthopedic innovations, Exactech is focused on pushing technological boundaries to deliver a best-in-class platform of enabling technologies and smart solutions. With a commitment to research and transformative technologies, such as a first-to-market surgical guidance system, machine learning-based tools and personalized planning solutions, we are delivering on our vision to unlock data insights through platform-independent, economical innovations that improve clinical outcomes .”

    Active Intelligence was launched in 2021 as a dynamic ecosystem of enabling technologies and smart solutions that provides unparalleled support to surgeons in and outside the operating room. With powerful scheduling software, prediction tools, disruptive surgical technologies and engagement capabilities, Exactech AI provides surgeons with data-rich, low-cost solutions that help improve patient outcomes.

    Some notable achievements of Exactech AI include:

    • Informed by the collective intelligence of thousands of surgeries, powerful tools have enabled more than 2,500 personalized patient predictions by more than 450 surgeons around the world.
    • Personalized preoperative planning software, expanded globally this year, allows surgeons to plan the placement of shoulder components and select implants and sizes for the scapula and humerus based on each patient’s specific anatomy.
    • At no capital cost, more than 500 GPS stations are used by thousands of surgeons in hospitals and ASC centers around the world, and in nearly half of Exactech shoulder cases.
    • Modern alignment philosophies are supported by our ligament-controlled Newton Knee platform, now used in more than half of our guided, personalized knee surgeries.
    • A unique clinical exchange app connects all Exactech surgeons worldwide.

    For more information, visit www.ExactechAI.com.

    ExactechGPS, Equinoxe Planning App and Predict+ are developed by Blue Ortho, a subsidiary of Exactech, and distributed by Exactech, Inc.

    About Exactech

    Exactech is a global medical device company that develops and markets orthopedic implant devices, related surgical instruments and the Active Intelligence® platform of smart technologies for hospitals and physicians. Headquartered in Gainesville, Florida, Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Visit www.exac.com for more information and connect with us on LinkedIn, Vumedi, YouTube, Instagram and Tweet. With Exactech by your side you have EXACTLY what you need.

    Contacts

    Courtney Adkins
    Director of Marketing Communications
    media@exac.com

    Photo: Business Wire



    Source link

  • The effectiveness of phase I cardiac rehabilitation training based on augmented reality on the self-efficacy of patients undergoing coronary artery bypass surgery: a randomized clinical trial |  BMC Sports sciences, medicine and rehabilitation

    The effectiveness of phase I cardiac rehabilitation training based on augmented reality on the self-efficacy of patients undergoing coronary artery bypass surgery: a randomized clinical trial | BMC Sports sciences, medicine and rehabilitation

    Trial design

    This controlled pilot clinical study involved 60 patients admitted to Ghaem Hospital of Mashhad, Iran. These patients were specifically from the cardiac surgery intensive care unit and were admitted between May 2020 and January 2021 (Figure 1).

    figure 1
    Figure 1

    CONSORT Flowchart of participants

    Attendees

    The study included patients who met specific inclusion criteria. These criteria required that patients be between 18 and 60 years old and willing to undergo non-emergency coronary transplant surgery. On the other hand, the exclusion criteria included patients who experienced loss of consciousness until the day after surgery, those who did not have a smartphone, individuals with severe postoperative arrhythmias and hemodynamic disorders, and patients who were prohibited by their physicians from participating in rehabilitation.

    Intervention

    Software production

    Prior to the design of the software, extensive research was done to prepare its contents. This involved reviewing various texts, including articles, reference works, and gathering insights from experienced nurses in specialist care units. The content was then submitted to a panel of ten specialists for validation, and their suggested revisions were incorporated.

    The software’s educational content covered a range of topics, including breathing and diaphragm exercises, instructions on physical exercises and their proper performance, discussions and interactions with patients, and encouragement for patients to participate in routine activities. These concepts were presented primarily through instructional videos and engaging animations.

    Once the content was ready, it was handed over to the software development and information technology team for creating the software. After the initial software was developed, a specialized validation process was carried out by ten IT experts to ensure its functionality and effectiveness.

    To validate the software, both white-box and black-box testing methods were used. In black-box testing, users without knowledge of the software’s internal structure enter the desired items and verify the recorded information. The purpose is to ensure accurate data recording. White-box testing, on the other hand, requires users to have knowledge of the software’s internal structure and is typically performed by designers or experts. For example, to assess the speed of the software, several items were selected at different speeds and the accuracy of the selections was examined.

    The next phase included compatibility testing and security testing. Compatibility testing involved installing the application on multiple Android smartphones and tablets to assess performance on each device. In the security testing, a double confirmation method was implemented to ensure accurate recording of each patient’s problems. This required the patient to confirm the selected item by clicking again, which reduced the chance of inadvertent data entry errors.

    The augmented reality software is registered and approved within the electronic services system of the Information Technology Organization of Iran.

    To evaluate patient satisfaction with the augmented reality software, the Mobile Application Rating Scale (MARS) was used.

    This scale evaluates the quality and performance of the application on four dimensions: attractiveness (5 questions), functionality (4 questions), aesthetics (3 questions), information (7 questions) and subjective quality (4 questions). Each item in the scale was rated on a five-point scale. The maximum achievable score was 115, while the minimum acceptable score was set at 23. For a detailed presentation of the results, please refer to (Table 1).

    Table 1 Mean and standard deviation of dimensions of MARS questionnaire

    Phase I cardiac rehabilitation training based on augmented reality

    After establishing the necessary agreements with officials at Ghaem Hospital in Mashhad, Iran, the first author of the study initiated the sampling process. In the intervention group, rehabilitation program training began upon patient entry into the cardiac surgery intensive care unit and continued until the patient’s discharge.

    During several sessions, augmented reality software was used to train patients in physical activities, such as walking around the hospital ward and climbing stairs. These exercises were performed under the direct supervision of the researcher and were taught individually to each patient using the augmented reality software. The duration of physical activity varied depending on the patient’s condition and the length of hospital stay, ranging from 5 to 10 minutes. During the rehabilitation sessions, the ECG and perceived exercise intensity were closely monitored and controlled.

    In the control group, the rehabilitation training program was implemented using a routine method based on the Ministry of Health protocol. The researcher provided face-to-face training within the unit. Both the intervention and control groups completed the cardiac self-efficacy questionnaire upon admission and discharge to the special care cardiac surgery department.

    Results

    The data collection process used two demographic information questionnaires and a cardiac self-efficacy questionnaire.

    The cardiac self-efficacy questionnaire used in this study was the Cardiovascular Management Self-Efficacy Questionnaire, which was developed by Estka of Italy in 2015. This questionnaire consists of 9 questions, each rated on a 5-point Likert scale, ranging from ‘completely confident’ to ‘not at all confident’. The questionnaire consists of three subscales.

    The first four questions assess a person’s belief in their ability to quit smoking, maintain good nutrition, exercise, and avoid stressful situations. This subscale is called cardiac risk factor self-efficacy. Questions 5 and 6 relate to a person’s confidence in remembering to take medications correctly, which reflects self-efficacy for medication adherence. Finally, questions 7 through 9 evaluate a person’s belief in their ability to identify symptoms and signs of disease worsening, indicating self-efficacy in recognizing symptoms.

    Each answer is assigned a score, with ‘not at all confident’ given a score of one, ‘somewhat confident’ given a score of two, ‘somewhat confident’ given a score of three, ‘fairly confident’ given a score of four, and “completely confident” with a score of five. Total scores range from 9 to 45, with higher scores indicating greater self-efficacy in cardiovascular management [21]. Borzou et al. (2017) evaluated the validity and reliability of this tool in Iran [33]. Patients completed the Cardiovascular Management Self-Efficacy Questionnaire both before and after the intervention.

    Sample size and randomization

    The study involved the continuous and purposeful selection of patients who were then randomly assigned to one of two groups. After confirming that they met the inclusion criteria, eligible individuals were divided into intervention and control groups using a random sequence generated by SPSS software. This series was kept in a sealed envelope to ensure confidentiality. Although it was challenging to blind the participants in this study, the outcome assessors and statisticians were unaware of the type of intervention, ensuring a level of objectivity.

    Because no comparable study was found examining the effectiveness of phase I cardiac rehabilitation training based on augmented reality on the self-efficacy of patients undergoing coronary artery bypass surgery, a sample size of 10 participants was determined for each group. The sample size was calculated using the mean comparison formula, with a 95% confidence interval and 80% test power for each group, resulting in a total of 20 participants. To account for the potential dropout rate, an additional 30 participants were added to each group, representing a 10% increase over the values ​​calculated in the formula.

    $$N = \text \left( Z1 – \alpha /2\text + \text Z1 – \beta \right)2\text \left ( S12\text + \text S22 \right)/\left( X1 – X2 \right)2$$

    $$Z_1 – \alpha /2 = \text 196$$

    $$Z_1 – \beta = \text 0.85$$

    $$X_2 = \text 8.3$$

    statistical methods

    After data collection and sampling, the collected data was analyzed using SPSS 21. Various statistical tests were used, including the independent t-test, the Mann-Whitney test, the paired t-test, and the chi-square test. These tests were performed at a 95% confidence level to ensure statistical significance. Descriptive indicators such as mean, standard deviation and frequency were also used to provide a comprehensive overview of the data. Cohen’s d was also used to evaluate the magnitude of the effect size, calculated by standardized mean difference, with g > 0.2 to 0.5 = small effect size, g > 0.5 to 0.8 = medium effect size, and g > 0 .8 = large effect size [38].

    Source link

  • PathKeeper Surgical is celebrating the first spine surgery performed with the PathKeeper 3D optical navigation system in Massachusetts

    PathKeeper Surgical is celebrating the first spine surgery performed with the PathKeeper 3D optical navigation system in Massachusetts

    The PathKeeper 3D optical navigation system is used to improve the clinical experience, increase surgical accuracy and eliminate radiation exposure during spine surgery.

    KFAR SABA, Israel, Nov. 16, 2023 /PRNewswire/ — PathKeeper Surgical, a privately held, Israel-based medical technology company, is committed to improving the health of people around the world suffering from all spinal problems requiring surgery. As PathKeeper Surgical celebrates the first use of the PathKeeper 3D optical navigation system during spinal fusion surgery at Southcoast Health’s St. Luke’s Hospital in New Bedford, Massachusetts, PathKeeper Surgical is committed to making navigation-guided surgery available to every patient in all operating rooms.

    The PathKeeper system was used to create a comprehensive surgical plan and accurately navigate the single-level lumbar degenerative spinal fusion surgery at Southcoast Health’s St. Luke’s Hospital.

    “The PathKeeper system addresses many of the complexities of spine surgery and adapts to the patient’s individual needs with a high degree of accuracy and without radiation during a critical part of the surgical procedure,” said Matthew Philips, MD, chief of Brain & Spine Services, Southcoast Health Neurosurgery, Dartmouth, MA. “We have already experienced the clinical benefits of integrating the PathKeeper system into our spinal fusion surgeries at St. Luke’s Hospital.”

    The PathKeeper system is designed to replace traditional navigation technology with a 3D optical navigation system that provides comprehensive surgical planning; active, independent submillimeter registration and tracking of patient anatomy and surgical instruments; establish precise accuracy of device implantation; more efficient surgical workflow; elimination of radiation exposure during the surgical procedure; and a more affordable price point so that both hospital operating rooms and ambulatory surgical center operating rooms can integrate this new technology.

    “We are very pleased with the adoption of the PathKeeper system at Southcoast Health, which continues our expansion of the PathKeeper system to hospitals and surgery centers across the United States,” said Ryan LeBlanc, Chief Commercial Officer of PathKeeper Surgical. “The PathKeeper system is a game changer in driving improved clinical outcomes and economic value for patients and healthcare providers.”

    PathKeeper Surgical received FDA 510k clearance for the PathKeeper System earlier this year. The name PathKeeper effectively describes the essence of the system: a 3D optical navigation system that ‘keeps’ the surgical ‘path’ on course throughout the operation.

    About PathKeeper Surgical
    PathKeeper Surgical is an Israel-based medical technology company that has developed a solution to combat the high failure rates in spine surgery. PathKeeper was founded in 2018 by Erez Lampert, a top expert in medical 3D imaging with more than 20 years of experience in the healthcare and aerospace industries, and a proven track record in 3D imaging. Erez previously served as R&D leader for the Itero Element Intraoral Scanner for Align Technology (Invisalign), the world’s leading 3D dental scanner. Josh Schroeder, MD, director of Spinal Deformities at Hadassah Medical Center and an HSS fellow, has been on board as a clinical advisor since the company’s founding. Erez and Josh’s combined knowledge enabled the company to develop an innovative navigation system that outperforms existing solutions. More information can be found at path-keeper.com.

    About Southcoast Health
    For more than 25 years, Southcoast Health has served communities in southeastern Massachusetts and Rhode Island as the region’s largest provider of primary and specialty care. The nonprofit charity system includes three acute care hospitals – Charlton Memorial in Fall River, St. Luke’s in New Bedford (a Level II Trauma Center) and Tobey in Wareham – as well as a network of more than 700 physicians, hospitalists and mid-level practitioners.

    Southcoast Health has established six urgent care centers, two cancer centers, a Visiting Nurse Association and numerous outpatient facilities that ensure convenient access to services for 725,000 residents in 33 communities covering 900 square miles. Additionally, the system has partnered with Acadia Healthcare to provide expanded resources at Southcoast Behavioral Health in Dartmouth.

    Southcoast Health has been consecutively recognized as a Newsweeks World’s Best Hospital of 2019-2023, in addition to being ranked as a High Performing Hospital for Maternity Care during the calendar years 2021-2022 and 2022-2023 by American news and world report.

    With more than 7,500 employees, Southcoast Health is the largest employer in southeastern Massachusetts and one of the largest employers in the Commonwealth, according to the Boston Business Journal. More information is available online at www.southcoast.org.

    US Media Contact:
    Ryan LeBlanc
    head of marketing
    ryan.leblanc@path-keeper.com

    Photo – https://mma.prnewswire.com/media/2279117/PathKeeper.jpg

    SOURCE PathKeeper

    Source link

  • The assessment of atlantoaxial joint involvement in patients with rheumatoid arthritis is the result of an observational ‘real-life’ study

  • Smolen, JS, Aletaha, D. & McInnes, IB Rheumatoid arthritis. Lancet 3882023–2038 (2016).

    Article CAS PubMed Google Scholar

  • Scott, DL, Wolfe, F. & Huizinga, TW Rheumatoid arthritis. Lancet 3761094–1108 (2010).

    Article PubMed Google Scholar

  • Garrod, A.E A treatise on rheumatism and rheumatoid arthritis (Griffin’s medical series, 1890).

    Google Scholar

  • Shlobin, NA & Dahdaleh, NS Cervical spine manifestations of rheumatoid arthritis: a review. Neurosurgeon. Rev. 441957–1965 (2021).

    Article PubMed Google Scholar

  • Kim, HJ, Nemani, VM, Riew, KD & Brasington, R. Cervical spine disease in rheumatoid arthritis: incidence, manifestations and therapy. Current Rheumatoid. Rep. 179 (2015).

    Article PubMed Google Scholar

  • Chattopadhyay, A., Samanta, J., Jindal, A. & Jain, S. Neck pain in rheumatoid arthritis: a look beyond cervical spine involvement. Rheumatology (Oxford) 60471 (2021).

    Article PubMed Google Scholar

  • Carotti, M., Salaffi, F., Di Carlo, M., Sessa, F. & Giovagnoni, A. Magnetic resonance imaging of the craniovertebral junction in early rheumatoid arthritis. Skeleton. Radiol. 48553–561 (2019).

    Article Google Scholar

  • Drosos, AA, Pelechas, E. & Voulgari, PV Radiological findings of the cervical spine in rheumatoid arthritis: what a rheumatologist should know. Current Rheumatoid. Rep. 2219 (2020).

    Article PubMed Google Scholar

  • Kaito, T. et al. Incidence and risk factors for cervical lesions in patients with rheumatoid arthritis under the current pharmacological treatment paradigm. Mod. Rheumatoid. 27593–597 (2017).

    Article CAS PubMed Google Scholar

  • Montemerani, M. et al. Involvement of the atlantoaxial joint in rheumatoid arthritis: rare or frequent? Klin. Rheumatoid. 13459–463 (1994).

    Article CAS PubMed Google Scholar

  • Zhang, T. & Pope, J. Involvement of the cervical spine in rheumatoid arthritis over time: results from a meta-analysis. Arthritis Res. Over there. 17148 (2015).

    Article PubMed PubMed Central Google Scholar

  • Aletaha, D. et al. 2010 Rheumatoid Arthritis Classification Criteria: A Collaborative Initiative of the American College of Rheumatology/European League Against Rheumatism. Ann. Rheum. Dis. 691580–1588 (2010).

    Article PubMed Google Scholar

  • Duru, N. et al. EULAR evidence-based and consensus recommendations for the treatment of moderate to high dose glucocorticoid therapy in rheumatic diseases. Ann. Rheum. Dis. 721905–1913 (2013).

    Article CAS PubMed Google Scholar

  • Peduzzi, P., Concato, J., Kemper, E., Holford, TR & Feinstein, AR A simulation study of the number of events per variable in logistic regression analysis. J. Clin. Epidemiol. 491373–1379 (1996).

    Article CAS PubMed Google Scholar

  • Groenland, S., Schwartzbaum, J. A. & Finkle, W. D. Problems due to small sample sizes and sparse data in conditional logistic regression analysis. Ben. J. Epidemiol. 1(151), 531-539 (2000).

    Article Google Scholar

  • Joaquim, A. F., Ghizoni, E., Tedeschi, H., Appenzeller, S. & Riew, K. D. Radiological evaluation of cervical spine involvement in rheumatoid arthritis. Neurosurgeon. Focus 38E4 (2015).

    Article PubMed Google Scholar

  • Castro, S. et al. Cervical spine involvement in rheumatoid arthritis: a clinical, neurological and radiological evaluation. Klin. Execution Rheumatoid. 12369–374 (1994).

    CAS PubMed Google Scholar

  • Baek, IW, Joo, YB, Park, KS & Kim, KJ Risk factors for cervical spine instability in patients with rheumatoid arthritis. Klin. Rheumatoid. 40547–555 (2021).

    Article PubMed Google Scholar

  • Kotecki, M., Gasik, R., Głuszko, P. & Sudoł-Szopińska, I. Radiological evaluation of cervical spine involvement in rheumatoid arthritis: a cross-sectional retrospective study. J. Clin. Med. 104587 (2021).

    Article CAS PubMed PubMed Central Google Scholar

  • Hyrich, KL, Watson, KD, Silman, AJ, Symmons, DP, British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-alpha therapy in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 451558-1565 (2006).

    Article CAS PubMed Google Scholar

  • Kvien, TK, Uhlig, T., Ødegård, S. & Heiberg, M. S. Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann. NY Acad. Science 1069212–222 (2006).

    Article ADS PubMed Google Scholar

  • Mancarella, L. et al. Good clinical response, remission and predictors of remission in patients with rheumatoid arthritis treated with tumor necrosis factor alpha blockers: the GISEA study. J. Rheumatol. 341670–1673 (2007).

    CAS PubMed Google Scholar

  • Kocijan, R., Harre, U. & Schett, G. ACPA and bone loss in rheumatoid arthritis. Current Rheumatoid. Rep. 15366 (2013).

    Article PubMed Google Scholar

  • Katchamart, W., Koolvisoot, A., Aromdee, E., Chiowchanwesawakit, P. & Muengchan, C. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis. Rheumatoid. Int. 351693–1699 (2015).

    Article CAS PubMed Google Scholar

  • Symmonen, D. et al. Patients with stable, long-standing rheumatoid arthritis continue to deteriorate despite increased treatment with traditional disease-modifying anti-rheumatic drugs – Results from the British Rheumatoid Outcome Study Group randomized controlled clinical trial. Rheumatology (Oxford) 45558-565 (2006).

    Article CAS PubMed Google Scholar

  • Turesson, C. Extra-articular rheumatoid arthritis. Current opinion. Rheumatoid. 25360–366 (2013).

    Article CAS PubMed Google Scholar

  • Conforti, A. et al. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmune. Rev. 20102735 (2021).

    Article PubMed Google Scholar

  • Bruno, F. et al. New developments in MRI diagnosis of degenerative osteoarthropathy of the peripheral joints. Radiol. Of. 1241121–1127 (2019).

    Article PubMed Google Scholar

  • Østergaard, M. & Boesen, M. Imaging in rheumatoid arthritis: the role of magnetic resonance imaging and computed tomography. Radiol. Of. 1241128–1141 (2019).

    Article PubMed Google Scholar

  • Bariel, A. et al. Computed tomography and MR imaging in rheumatoid arthritis. Radiol. Klin. North Am. 55997–1007 (2017).

    Article PubMed Google Scholar

  • Bruno, F. et al. MR imaging of the upper limb: pitfalls, tricks and tips. Radiol. Klin. North Am. 571051–1062 (2019).

    Article PubMed Google Scholar

  • Buch, MH Defining refractory rheumatoid arthritis. Ann. Rheum. Dis. 77966–969 (2018).

    Article CAS PubMed Google Scholar

  • Shop, MJ et al. Rheumatoid atlantoaxial subluxation can be prevented by intensive use of traditional disease-modifying antirheumatic drugs. J. Rheumatol. 36273–278 (2009).

    Article PubMed Google Scholar

  • Kaito, T. et al. Effect of biological agents on cervical spine lesions in rheumatoid arthritis. Spine (Phila Pa 1976) 371742–1746 (2012).

    Article PubMed Google Scholar

  • Kanayama, Y. (1999). et al. Radiographic progression of cervical lesions in patients with rheumatoid arthritis treated with infliximab. Mod. Rheumatoid. 20273–279 (2010).

    Article PubMed Google Scholar

  • Wasserman, BR, Moskovich, R. & Razi, AE Rheumatoid arthritis of the cervical spine – Clinical considerations. Taurus. NYU Hospital. Jt. Dis. 69136–148 (2011).

    PubMed Google Scholar

  • Cipriani, P. et al. Biological therapies and infections in daily practice of three Italian rheumatology units: a prospective, observational study. Klin. Rheumatoid. 36251–260 (2017).

    Article PubMed Google Scholar

  • Giacomelli, R. et al. Guidelines for biomarkers in autoimmune rheumatic diseases: evidence-based analysis. Autoimmune. Rev. 1893–106 (2019).

    Article CAS PubMed Google Scholar

  • Giacomelli, R. et al. International consensus: what more can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjögren’s syndrome)?: The unmet needs and the clinical gray zone in the treatment of autoimmune diseases. Autoimmune. Rev. 16911–924 (2017).

    Article PubMed Google Scholar

  • Giacomelli, R. et al. The growing role of precision medicine for the treatment of autoimmune diseases; Results of a systematic review of literature and expert consensus. Autoimmune. Rev. 20102738 (2021).

    Article CAS PubMed Google Scholar

  • Source link

  • Part 2 (Alignment) — Bone Talk

    Part 2 (Alignment) — Bone Talk

    shutterstock 614185925

    Training Your Bones: Part 2 (Alignment)
    By Rebekah Rotstein, NCPT

    Last month we went exploring how exercise benefits your bones, noting the importance of consistency, progression, and enjoyment in your routine. We identified the three methods of building bone tissue: weight-bearing movement, resistance exercise and impact activities.

    But focusing only on these elements overlooks an important part of essential training programming for bone health: body alignment, and more specifically, joint positioning.

    Suppose you are used to standing with your ribs pressed forward, and think that this is how you should present with good posture so that you do not slouch. This altered torso placement changes the muscle activation of your core muscles, recruiting the back and often inhibiting the abdominal muscles, causing both weakness and potential back strain over time. Adding heavier weight loads to that forced postural presentation can leave your body vulnerable to injury.

    From a bone health perspective, the beneficial forces from the weights may not be transmitted evenly through the spine and body in that distorted postural presentation. The better your skeleton is in a standing, weight-bearing position, the better its ability to optimize the loading forces of both gravity and external resistance. In other words, body alignment plays a role in bone strengthening.

    ALIGNMENT 101

    So how can you improve your body alignment? A great place to start is unloading your skeleton. If you have osteoporosis or osteopenia, and even more so if you have had a fracture in the past, decompress your spine daily by lying on your back with your knees bent. This is known as constructive rest position. Focus on your breathing here, spending anywhere from a few minutes to, say, 10 minutes a day. Make sure you provide proper head support if necessary to prevent neck strain.

    Then try the following exercises:

    Lying shoulder press
    -to improve posture and decompress the spine

    Lie on your back with your knees bent. Inhale with palms facing up, next to your hips. Exhale and gently press your shoulders into the mat for a few seconds. Inhale and release, then exhale and press again. Repeat several times.

    Source link